Vivani Medical Presents Development Plans for Once- or Twice-Yearly Semaglutide Implant

Bitget2026/10/29 15:47

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Vivani Medical expects top-line results from its SLIM-1 Phase 1 trial of semaglutide implant NPM-139 in November 2026.
All SLIM-1 patients were successfully dosed in August 2026; a Phase 2 dose-ranging study is projected to start in 2027.
NPM-139 targets once- or twice-yearly dosing for chronic weight management in obese or overweight patients.
Novo Nordisk's evaluation of NPM-139 remains ongoing.
Cash runway is expected to fund the current operating plan, including key milestones, into mid-2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivani Medical Inc. published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Vivani Medical Presents Development Plans for Once- or Twice-Yearly Semaglutide Implant

You may also like

Crypto prices